| Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson’s disease CK Nwabufo, OP Aigbogun Journal of neurology 269 (11), 5762-5786, 2022 | 15 | 2022 |
| Employing in vitro metabolism to guide design of F-labelled PET probes of novel α-synuclein binding bifunctional compounds CK Nwabufo, OP Aigbogun, KJH Allen, MN Owens, JS Lee, CP Phenix, ... Xenobiotica 51 (8), 885-900, 2021 | 10 | 2021 |
| Potential application of mass spectrometry imaging in pharmacokinetic studies CK Nwabufo, OP Aigbogun Xenobiotica 52 (8), 811-827, 2022 | 4 | 2022 |
| The Chemistry of Creating Chemically Programmed Antibodies (cPAbs): Site-Specific Bioconjugation of Small Molecules OP Aigbogun, CP Phenix, ES Krol, EW Price Molecular Pharmaceutics 20 (2), 853-874, 2023 | 2 | 2023 |
| An HPLC-UV validated bioanalytical method for measurement of in vitro phase 1 kinetics of α-synuclein binding bifunctional compounds OP Aigbogun, CK Nwabufo, MN Owens, KJH Allen, JS Lee, CP Phenix, ... Xenobiotica 52 (8), 916-927, 2022 | 1 | 2022 |
| The Bifunctional Dimer Caffeine-Indan Attenuates α-Synuclein Misfolding, Neurodegeneration and Behavioural Deficits After Chronic Stimulation of Adenosine A1 Receptors E Jakova, OP Aigbogun, MT Moutaoufik, KJH Allen, O Munir, D Brown, ... Preprints, 2024 | | 2024 |
| Design, Synthesis, and Preclinical Evaluation of Alpha-Synuclein Binding 19/18Fluorine Labelled Bifunctional/Trifunctional Agents as Potential Positron Emission Tomography … OP Aigbogun University of Saskatchewan, 2023 | | 2023 |
| Employing in vitro metabolism to guide design of F-labeled PET probes of novel α-Synuclein binding bifunctional compounds KJH Aigbogun, MN Owens, JS Lee, CP Phenix, ES Krol | | |
Chukwunonso NwabufoPhD Candidate and CIHR Scholar, University of Toronto; Founder and CEO, OneDrug Inc.在 mail.utoronto.ca 的电子邮件经过验证
